Debiopharm Group Taps Quartz Bio to Provide Bioinformatics Support for Biomarker Projects | GenomeWeb

Last week, Quartz Bio said that it had been selected to provide bioinformatics support for biomarker projects conducted by the Debiopharm group, a Swiss-based biopharmaceutical company.

Under the terms of the one-year agreement, the Merck Serono spinoff (BI 9/7/2012) will provide computational analyses for Debiopharm projects in areas such as preclinical next-generation sequencing and clinical biomarker data analyses.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.